Inner Cosmos Treating Depression With Neurotechnology

Inner
Cosmos Treating Depression
With Neurotechnology

Introducing
The Digital Pill First embedded BCI:
Least invasive Brain Computer Interface
designed for treating depression Learn more in our paper +

Introducing
The Digital Pill First embedded BCI:
Least invasive Brain Computer Interface
designed for treating depression Learn more in our paper+

First Clinical Trial For Depression
Approved By The FDA In 20 years

First Clinical Trial For
Depression Approved By
The FDA In 20 years

“My family and I have noticed a significant improvement in my mood. The overall atmosphere in the house has improved.”
Patient in human study, completed one year trial in remissionCEO

“The treatment became a seamless part of my daily routine. It doesn’t bother me at all; I can do anything during the day and stay active.”
Patient in human study, completed one year trial in remissionCEO

“⁠My mood has definitely been much better, significantly better, than it has been in the last few years.”
Patient in human study, completed one year trial in remissionCEO

“⁠Over the last few months, I’ve noticed my mood lifting. That constant weight I used to feel all the time is much lighter now.”
Patient in human study, completed one year trial in remissionCEO


Learn more about our human study +

In collaboration with

* ⁠Currently using proxy device for trial

Precision Tailored therapy that reads and stimulates brain networks, bringing them back into balance without invasive surgery.
Embedded Our Digital Pill seamlessly integrates into your lifestyle, invisible and unobtrusive. Mobile Therapy on the go. 
Our Digital Pill eliminates the need for multiple clinic visits. Benefits:

Precision Tailored therapy that reads and stimulates brain networks, bringing them back into balance without invasive surgery. Our Digital Pill seamlessly integrates into your lifestyle, invisible and unobtrusive. Embedded Mobile Therapy on the go. 
Our Digital Pill eliminates the need for multiple clinic visits. Benefits

Milestones

In 2011 Inner Cosmos co-founder psychiatrist Darin D. Dougherty of Harvard MGH co-authored an 11-subject study, demonstrating that an ECoG device has similar efficacy to TMS. Published paper of ECoG In 2016 Meron Gribetz, Dr. Eric Leuthardt, Dr. Dan Moran and Ted Kucklick came together with the idea of the Digital Pill, a minimally invasive in-bone device, that can be implanted in a one-hour outpatient procedure and provides results similar to or even better than TMS. Digital Pill invented Preclinical study #1 In 2016 co-founder Dan Moran’s lab used animal models to demonstrate how a thinned layer of bone can enable high gamma 75-105Hz range. In 2018 a second animal study led by Dr. Eric Leuthardt and Dr. Dan Moran quantified the stimulation parameters required by the Inner Cosmos device to elicit a response equivalent to TMS. Preclinical Study #2 In 2019 a one -year tissue resistance​ study was conducted showing bone and brain dynamics. Ovine Longitudinal Study (Preclinical #3) In 2021 the FDA approved the first Investigational Device Exemption (IDE) study for depression in almost 20 year, since Vagus Nerve Stimulation (VNS). FDA IDE-approval for Early Feasibility Study In 2022 Inner Cosmos implanted its first patient at the Washington University School of Medicine in St. Louis. The study proved that the device was safe and three different parameters were studied (DBS, ECoG and TMS). Early feasibility study, patient #1 In 2023 Inner Cosmos implanted its second patient, demonstrating the treatments effectiveness, leading the patient into remission after 17 years with severe depression. Early feasibility study, patient #2 In 2024 Inner Cosmos implanted its third patient, Studied 3 TMS prescriptions and personalized parameters. Early feasibility study, patient #3

Milestones

In 2011 Inner Cosmos co-founder psychiatrist Darin D. Dougherty of Harvard MGH co-authored an 11-subject study, demonstrating that an ECoG device has similar efficacy to TMS. Published Paper Of ECoG In 2016 the Inner Cosmos came together with the idea of the Digital Pill, a minimally invasive in-bone device, that can be implanted in a 1 hour outpatient procedure and provides results similar to or even better than TMS. Digital Pill Invented Preclinical Study #1 In 2016 Co-Founder Dan Moran’s lab used animal models to demonstrate how a thinned layer of bone can enable high gamma 75-105Hz range. In 2018 a second animal study led by Dr. Eric Leuthardt and Dr. Dan Moran quantified the stimulation parameters required by the Inner Cosmos device to elicit a response equivalent to TMS. Preclinical Study #2 Tissue resistance​ Study, showing bone and brain dynamics (1 yr) Longitudinal Study (Preclinical #3) Ovine Model First in almost 20 years since VNS First FDA IDE approved study for depression in 20 years activated at WashU. FDA IDE Approval For Early Feasibility Study In 2022, Inner Cosmos implanted its first patient at the Washington University School of Medicine in St. Louis. The study proved that the device was safe. Studied 3 prescriptions, DBS, ECoG and TMS parameters. Early Feasibility Study Patient #1 In 2023, Inner Cosmos implanted its second patient, demonstrating the treatments effectiveness, leading the patient into remission after 17 years with severe depression. Early Feasibility Study Patient #2 In 2024, Inner Cosmos implanted its third patient, Studied 3 TMS prescriptions and personalized parameters Early Feasibility Study Patient #3

Mission

Help humanity achieve
mental wellness and ensure our treatment is accessible to all

Watch keynote presentation +

Mission

Help humanity achieve mental wellness and ensure our treatment is accessible to all.

Watch keynote presentation +